The Pharma Data

AUGUST 1, 2025

Arrowhead’s Subsidiary Visirna Transfers Greater China Rights to Plozasiran to Sanofi in Strategic $395 Million Deal Amid Regulatory Milestone in Hypertriglyceridemia In a move poised to reshape the therapeutic landscape for patients with severe lipid disorders in China, Arrowhead Pharmaceuticals , Inc. President and CEO of Arrowhead. “We

Licensing

SugarCone Biotech

JUNE 19, 2025

Each target and each therapeutic modality induce varying degrees of clinical efficacy, as well as causing toxicities. Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets.

Therapies

Drug Target Review

MARCH 17, 2025

Neuropsychiatric treatment is on the verge of a major transformation. Historically, treatment options have been limited, with patients relying on daily medications that have minimal efficacy and troublesome side effects. This has sparked the development of a new approach to treating neuropsychiatric disorders.

Treatment

The Pharma Data

JUNE 18, 2025

Alnylam Elevates Dr. Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D.,

RNA

Drug Target Review

JULY 18, 2025

Immuno-oncology has transformed cancer treatment, but for many patients, tumours remain resistant to even the most advanced immune checkpoint inhibitors. DT-7012 retains its depletion activity even in high CCL1-concentrated environments – an essential property not shared by most competitor antibodies currently in clinical development.”

Medical Chemistry

The Pharma Data

JUNE 18, 2025

Metastatic castration-resistant prostate cancer represents the most advanced and lethal form of the disease, defined by progression despite androgen deprivation therapy and subsequent ARPI treatment. This has created an urgent need for more effective and tolerable treatments for this population.

Trials

The Pharma Data

JUNE 22, 2025

Engineered by Chugai Pharmaceutical Co., a subsidiary of the Roche Group, NXT007 represents a next-generation therapeutic approach that builds upon the foundation established by Hemlibra® (emicizumab), Roche’s first-in-class bispecific antibody approved for prophylactic treatment of hemophilia A.

Clinical Trials

The Pharma Data

AUGUST 1, 2025

This partnership brings together Altasciences’ extensive expertise in preclinical research and early clinical development with VoxCell’s groundbreaking tissue engineering technology, promising to deliver a more human-relevant, predictive, and efficient drug development paradigm. Source Link

Drug Development

The Pharma Data

JUNE 23, 2025

This study explored the effects of beginning treatment with lower starting doses of MariTide to improve tolerability while maintaining clinical benefit. Both data sets now provide foundational insight into the design and direction of Amgen’s upcoming Phase 3 MARITIME clinical development program.

Trials

The Pharma Data

JUNE 24, 2025

This dual-pronged approach allows Revolution Medicines to access capital tailored to its evolving needs without relinquishing equity or ceding commercial rights to a larger pharmaceutical partner. In doing so, Revolution Medicines aims to meet the needs of larger patient populations who currently have few, if any, targeted treatment options.

Drug Development

The Pharma Data

JUNE 11, 2025

Ionis Begins Pivotal Phase 3 REVEAL Study of ION582 in Angelman Syndrome, Dosing First Patient in Global Trial Ionis Pharmaceuticals , Inc. Currently, treatment options are limited to supportive care aimed at managing symptoms rather than targeting the underlying cause.

Trials

The Pharma Data

JUNE 24, 2025

This significant financial infusion is designed to fuel Revolution Medicines’ ambitious clinical development and commercialization plans, with a particular focus on its groundbreaking RAS(ON) inhibitor programs for patients with RAS-addicted cancers.

Clinical Development

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D

The Pharma Data

JUNE 6, 2025

JCR Pharmaceuticals Celebrates 50 Years of Innovation with Global Website Launch That Reflects Its Expanding Reach and Human-Centric Mission As JCR Pharmaceuticals commemorates its 50th anniversary, the global specialty biopharmaceutical company is marking this major milestone with the launch of a newly designed global website.

Pharmaceuticals

DrugBank

JUNE 18, 2025

While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. Developing a new drug takes an average of 10–15 years and costs upwards of $2 billion, yet the majority of drug candidates fail before reaching regulatory approval.

Drug Development

The Pharma Data

JULY 2, 2025

BioMarin Finalizes Acquisition of Inozyme Pharma, Strengthening Rare Disease Portfolio with INZ-701 BioMarin Pharmaceutical Inc. BioMarin, a recognized leader in the development of therapies for genetic conditions, believes that INZ-701 has the potential to become a first-in-class treatment for this serious disease.

Therapies

Drug Target Review

JULY 29, 2025

Effective financial management is a cornerstone in the success of clinical trials, which are integral to the advancement of drug discovery. As the pharmaceutical and biotech industries continue to evolve, clinical trials become more complex, and the importance of robust financial oversight has never been clearer.

Clinical Trials

DrugBank

JULY 14, 2025

Understanding the pharmacokinetics and pharmacodynamics of each drug in these complex regimens is critical to ensure safe and effective treatment.    Challenges in Managing Drug-Drug Interactions in Clinical Development Predicting and managing DDI in clinical trials is one of the most complex challenges in drug development.

Clinical Development

The Pharma Data

AUGUST 3, 2025

Dr. Nielsen officially joins the company on August 1, 2025, and will oversee Genmab’s operations in Germany—Europe’s largest pharmaceutical market and a pivotal launchpad for biotech growth in the region. Germany, as Europe’s largest economy and a leader in pharmaceutical innovation, represents a natural first step in that evolution.

Therapies

BioPharma Drive: Drug Pricing

JUNE 11, 2025

Published June 11, 2025 Ben Fidler Senior Editor post share post print email license The FDA on June 11, 2025 approved Nuvation's Ibtrozi for ROS1-positive non-small cell lung cancer.

FDA

New Drug Approvals

MAY 15, 2025

5] [7] [8] It is the first approved medication for the treatment of activated PI3K delta syndrome. [5] 5] [7] [8] It is the first approved medication for the treatment of activated PI3K delta syndrome. [5] 2] [5] It is a kinase inhibitor [2] [6] that is taken by mouth. [2] mmol) in CH 2 CI 2 (100 mL), was added TFA (41.8 24 March 2023.

FDA Approval

New Drug Approvals

JULY 8, 2025

1428321-10-1 Pritelivir mesylate is an antiviral drug currently under development, specifically targeting herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). It is being investigated as a potential treatment for various herpes infections, including those resistant to traditional antivirals like acyclovir.

Virus

SugarCone Biotech

JULY 6, 2025

Each target and each therapeutic modality induces varying degrees of clinical efficacy, as well as causing toxicities. Finally, while there are clear front runners among the pharmaceutical companies developing targeted therapeutics for these antigens there are also emerging biotechs aggressively pursuing these targets.

Drug Development

The Pharma Data

JUNE 20, 2025

The ARANOTE trial was designed to evaluate the efficacy and safety of darolutamide in a chemotherapy-free regimen for men with metastatic hormone-sensitive prostate cancer—a population in urgent need of effective, tolerable, and individualized treatment options.

Trials

Drug Target Review

MAY 26, 2025

Daniel Galbraith, Chief Scientific Officer at Solvias , brings extensive expertise in the pharmaceutical and biotechnology sectors. In his role, he provides both strategic and technical guidance to Solvias, a global Contract Research Organisation (CRO) that offers critical analytical services to the pharmaceutical industry.

Drug Development

Drug Target Review

MAY 5, 2025

Millions of people around the world each year face serious illness, with the promise of groundbreaking treatment being just out of reach. We have seen how quickly vaccines and treatments can be developed when innovation is prioritised and stakeholders work together against the backdrop of imminent societal needs.

Clinical Development

BioPharma Drive: Drug Pricing

JULY 10, 2025

Spencer Platt via Getty Images The first marketed treatment for the insatiable hunger associated with Prader-Willi disease is selling more quickly than Wall Street analysts expected, an early, but encouraging sign of demand. Condulis, for instance, predicts Vykat could reach $2.5 billion in worldwide yearly sales at its peak.

Drugs

PPD

APRIL 14, 2025

Medical researchers and practitioners see in their own patients how these ailments interconnect and overlap, as do the pharmaceutical and biotech companies working to develop GLP-1 therapeutics. Were applying that expertise and commitment to every aspect of developing and running successful GLP-1 studies.

Clinical Trials

BioPharma Drive: Drug Pricing

JUNE 24, 2025

Dive Insight: Lexeo is developing treatments for heart conditions, such as cardiomyopathy associated with Friedreich’s ataxia and plakophilin-2 arrhythmia. But the steady expansion of their use has slowed and, despite much trying, pharmaceutical companies have largely failed to top the drugs’ successes. Can they keep it?

RNA

PPD

SEPTEMBER 16, 2024

The pharmaceutical industry is currently experiencing a significant transformation. The convergence of real-world data (RWD), technology and artificial intelligence (AI) is playing a vital role in accelerating drug development. Ready to learn more about convergence of real-world data and technology for clinical trials?

Clinical Development

Drug Target Review

OCTOBER 11, 2023

More than 7,000 rare diseases – conditions that affect fewer than 1 in 2,000 people – have been identified, and1 in 17 people will develop a rare disease in their lifetime, with children disproportionately affected. Most of these conditions are genetic in origin and the majority have no effective treatment.

Disease

BioPharma Drive: Drug Pricing

JUNE 23, 2025

This shift raises ethical questions around prioritizing supply for diabetes patients versus those seeking treatment for obesity or cosmetic weight loss. The balance is complex, as obesity carries its own serious health risks. Additionally, preserving lean muscle mass during weight loss is a key area of focus to improve patient outcomes.

Treatment

Fierce BioTech

JULY 19, 2023

Through real-world use cases and thought-provoking discussions, we will showcase the power of AI in revolutionizing R&D processes and improving outcomes in the ever-evolving world of pharmaceuticals with emphasis on: Application of AI powered processes. Accelerating time to treatment. Drive operational efficiencies.

Clinical Development

Drug Hunter

JUNE 5, 2023

Recent Applications of Ring-Closing Metathesis in Drug Discovery and Development A selection of representative macrocycles in drug discovery where ring-closing metathesis has been applied to their synthesis are shown below, highlighting chemically diverse macrocycles from programs that have reached clinical development.

Process Chemistry

Drug Target Review

JANUARY 8, 2024

Following that work, it was discovered by Dr David Sinclair’s lab at Harvard that turning on only three of the four factors (OSK; Oct4, Sox2, Klf4) is the sweet spot for developing therapeutics where you can partially reprogram cells and restore cells to a more youthful state, while maintaining cell identity.

Science

The Pharma Data

OCTOBER 21, 2020

and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. Kimberly Smith, M.D., About the long-acting regimen of cabotegravir and rilpivirine.

Clinical Development

The Pharma Data

MAY 8, 2021

Sandoz, a Novartis division, today announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT, a clinical Phase III confirmatory efficacy and safety study, shortly 1. Aflibercept is a key treatment in ophthalmology.

Biosimilars